相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma
Y. Zheng et al.
LEUKEMIA (2013)
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma
Jianfei Qian et al.
BLOOD (2012)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function
Yu-Tzu Tai et al.
BLOOD (2012)
CD48 as a novel molecular target for antibody therapy in multiple myeloma
Naoki Hosen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
William Bensinger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
Amrita V. Kamath et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Interleukin-6 signaling pathway in targeted therapy for cancer
Yuqi Guo et al.
CANCER TREATMENT REVIEWS (2012)
Incorporating Monoclonal Antibodies Into the Therapy of Multiple Myeloma
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab attenuates major signaling cascades and elF4E translation initiation factor in multiple myeloma cells
Oshrat Attar-Schneider et al.
LABORATORY INVESTIGATION (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
N. W. C. J. van de Donk et al.
LEUKEMIA (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets
S. Berardi et al.
ONCOGENE (2012)
In Silico Investigations of the Anti-Catabolic Effects of Pamidronate and Denosumab on Multiple Myeloma-Induced Bone Disease
Yan Wang et al.
PLOS ONE (2012)
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
Caroline Rousseau et al.
TUMOR BIOLOGY (2012)
Multiple myeloma: improved outcomes with new therapeutic approaches
Shahrooz Eshaghian et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2012)
Targeting the Tumor Microenvironment: Focus on Angiogenesis
Fengjuan Fan et al.
JOURNAL OF ONCOLOGY (2012)
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial
George Somlo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Targeting cell surface β2-microglobulin by pentameric IgM antibodies
Yabing Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Monoclonal antibodies in the treatment of multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenstrom's Macroglobulinemia
Jean-Francois Rossi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies
Timothy A. Yap et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations
Kerry S. Campbell et al.
IMMUNOLOGY (2011)
Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-Kappa Multiple Myeloma with Tocilizumab
Yasushi Matsuyama et al.
INTERNAL MEDICINE (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
P. Moreau et al.
LEUKEMIA (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Inhibition of IGF-1 Signalling Enhances the Apoptotic Effect of AS602868, an IKK2 Inhibitor, in Multiple Myeloma Cell Lines
Ines Tagoug et al.
PLOS ONE (2011)
Antibody-Based Therapies in Multiple Myeloma
Yu-Tzu Tai et al.
BONE MARROW RESEARCH (2011)
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
Gareth Morgan
BLOOD REVIEWS (2010)
A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
Edmund A. Rossi et al.
CANCER RESEARCH (2010)
A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
Takahiro Ishiguro et al.
CANCER SCIENCE (2010)
NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients
Susanne E. Johansson et al.
CLINICAL IMMUNOLOGY (2010)
Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody
Jun Amano et al.
DRUG METABOLISM AND DISPOSITION (2010)
Humoral immunotherapy of multiple myeloma: perspectives and perplexities
Andrea Di Bernardo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Milatuzumab - a promising new immunotherapeutic agent
Zuzana Berkova et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
Mohamad Hussein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Macrophage Migration Inhibitory Factor Elicits an Angiogenic Phenotype in Human Ectopic Endometrial Cells and Triggers the Production of Major Angiogenic Factors via CD44, CD74, and MAPK Signaling Pathways
Veronique Veillat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Osteonecrosis of the Jaw in a Patient on Denosumab
Tara L. Aghaloo et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2010)
Activity of cetuximab as single agent in a patient with relapsed multiple myeloma
Boris Boell et al.
LEUKEMIA & LYMPHOMA (2010)
Long-term response to maintenance treatment with rituximab in CD20+ multiple myeloma
Hitoshi Ohno
LEUKEMIA & LYMPHOMA (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
Ravi Vij et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Denosumab in Osteoporosis and Oncology
Jill S. Burkiewicz et al.
ANNALS OF PHARMACOTHERAPY (2009)
The role of Dickkopf-1 in bone development, homeostasis, and disease
Joseph J. Pinzone et al.
BLOOD (2009)
被撤回的出版物: CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Retracted article. See vol. 115, pg. 2983, 2010)
Yu-Tzu Tai et al.
BLOOD (2009)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti et al.
BLOOD (2009)
Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study
J-F Rossi et al.
BRITISH JOURNAL OF CANCER (2009)
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
G. Descamps et al.
BRITISH JOURNAL OF CANCER (2009)
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
Peter M. Voorhees et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Wei Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Hiroshi Ikeda et al.
CLINICAL CANCER RESEARCH (2009)
Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2009)
A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Mariateresa Fulciniti et al.
CLINICAL CANCER RESEARCH (2009)
Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
D. Santini et al.
CURRENT CANCER DRUG TARGETS (2009)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
Deborah J. Heath et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Protective CD8 T Cell Memory Is Impaired during Chronic CD70-Driven Costimulation
Klaas P. J. M. van Gisbergen et al.
JOURNAL OF IMMUNOLOGY (2009)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma
Tina Damgaard et al.
LEUKEMIA & LYMPHOMA (2009)
Antibody-maytansinoid conjugates for the treatment of myeloma
Robert J. Lutz et al.
MABS (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
K. Noborio-Hatano et al.
ONCOGENE (2009)
Targeted therapies in multiple myeloma
Efstathios Kastritis et al.
TARGETED ONCOLOGY (2009)
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Mohammad Luqman et al.
BLOOD (2008)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Anti-CD20 monoclonal antibody therapy in multiple myeloma
Prashant Kapoor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
Julie A. McEarchern et al.
CLINICAL CANCER RESEARCH (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
The role of microenvironment in tumor angiogenesis
Domenico Ribatti et al.
GENES AND NUTRITION (2008)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors
F. Atzori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
COX-2 and CCR2 induced by CD40 ligand and MCP-1 are linked to VEGF production in endothelial cells
Seiji Futagami et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2008)
Regulation of Dendritic Cell Migration by CD74, the MHC Class II-Associated Invariant Chain
Gabrielle Faure-Andre et al.
SCIENCE (2008)
Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
S. Yaccoby et al.
LEUKEMIA (2008)
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
K. Podar et al.
ONCOGENE (2008)
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma
Peter M. Voorhees et al.
CLINICAL CANCER RESEARCH (2007)
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Maureen C. Ryan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined Immunodeficient human multiple myeloma model
Paola Neri et al.
CLINICAL CANCER RESEARCH (2007)
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor - Related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2
Mitchell R. Smith et al.
CLINICAL CANCER RESEARCH (2007)
The role of platelet/endothelial cell adhesion molecule-1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells
Nathalie Gallay et al.
CANCER RESEARCH (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Reply to rituximab activity in CD20 positive multiple myeloma
A. Gozzetti et al.
LEUKEMIA (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Heparanase enhances syndecan-1 shedding - A novel mechanism for stimulation of tumor growth and metastasis
Yang Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis
Robert J. Hoyer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3
Carmelo Carlo-Stella et al.
CANCER RESEARCH (2007)
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby et al.
BLOOD (2007)
Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor
Naoko Yoshio-Hoshino et al.
CANCER RESEARCH (2007)
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment
Etsuko Sekimoto et al.
CANCER RESEARCH (2007)
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A. McEarchern et al.
BLOOD (2007)
CD200 is a new prognostic factor in multiple myeloma
Jerome Moreaux et al.
BLOOD (2006)
Targeting β2-microglobulin for induction of tumor apoptosis in human hernatological malignancies
Jing Yang et al.
CANCER CELL (2006)
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
Emmanuelle Menoret et al.
BLOOD (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen
IM Sainz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
Angiogenesis in multiple myeloma
Christian Jakob et al.
EUROPEAN JOURNAL OF CANCER (2006)
Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma
Niklas Zojer et al.
LEUKEMIA & LYMPHOMA (2006)
Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
MS Zand et al.
BLOOD (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications
YT Tai et al.
CANCER RESEARCH (2005)
The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cγ signaling pathways in human NK cells
I Tassi et al.
JOURNAL OF IMMUNOLOGY (2005)
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma:: results of a pilot study including biological aspects
JF Rossi et al.
BONE MARROW TRANSPLANTATION (2005)
Drug-conjugated monoclonal antibodies for the treatment of cancer
JM Lambert
CURRENT OPINION IN PHARMACOLOGY (2005)
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
CL Law et al.
CANCER RESEARCH (2005)
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
J Moreaux et al.
BLOOD (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Phospholipase C-γ2 is a critical signaling mediator for murine NK cell activating receptors
I Tassi et al.
JOURNAL OF IMMUNOLOGY (2005)
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
YT Tai et al.
CANCER RESEARCH (2005)
Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229
M Martín et al.
JOURNAL OF IMMUNOLOGY (2005)
B cell receptor (BCR) cross-talk:: CD40 engagement creates an alternate pathway for BCR signaling that activates IκB kinase/IκBα/NF-κB without the need for PI3K and phospholipase Cγ
T Mizuno et al.
JOURNAL OF IMMUNOLOGY (2005)
Expression of EGF-family receptors and amphiregulin in multiple myeloma.: Amphiregulin is a growth factor for myeloma cells
K Mahtouk et al.
ONCOGENE (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Targeting signalling pathways for the treatment of multiple myeloma
K Podar et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
An epidermal growth factor receptor chimeric human-murine monoclonal antibody
J Harding et al.
DRUGS OF TODAY (2005)
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
S Bouralexis et al.
APOPTOSIS (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
A means to a DNA end: The many roles of Ku
JA Downs et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
YT Tai et al.
CANCER RESEARCH (2004)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis
P Martín et al.
HISTOPATHOLOGY (2004)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
K Mahtouk et al.
BLOOD (2004)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
CD74 is expressed by multiple myeloma and is a promising target for therapy
JD Burton et al.
CLINICAL CANCER RESEARCH (2004)
L2D7 diabody bound to the α2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells
N Kimura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
CMM Van Geelen et al.
DRUG RESISTANCE UPDATES (2004)
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
P Tassone et al.
BLOOD (2004)
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
R Stein et al.
BLOOD (2004)
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells
P Tassone et al.
CANCER RESEARCH (2004)
Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
Y Mori et al.
BLOOD (2004)
Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients
AM Santonocito et al.
LEUKEMIA RESEARCH (2004)
Following a TRAIL: Update on a ligand and its five receptors
FC Kimberley et al.
CELL RESEARCH (2004)
Therapy strategies for multiple myeloma: current status
H Gisslinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2003)
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
N Robillard et al.
BLOOD (2003)
Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma
S Hofer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
W Matsui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro
T Hirata et al.
LEUKEMIA RESEARCH (2003)
Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation
P Musto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses
BO Lee et al.
JOURNAL OF IMMUNOLOGY (2003)
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma
F Pene et al.
ONCOGENE (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells:: therapeutic implications
CS Mitsiades et al.
ONCOGENE (2002)
Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage
L Héron-Milhavet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation
SA Ely et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes
H Dadgostar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation
C Gemmel et al.
ANNALS OF HEMATOLOGY (2002)
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: Functional implications
YT Tai et al.
EXPERIMENTAL HEMATOLOGY (2002)
CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo
S Partida-Sánchez et al.
NATURE MEDICINE (2001)
Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion
R Arens et al.
IMMUNITY (2001)
The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity
Y Morel et al.
JOURNAL OF IMMUNOLOGY (2001)
The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells
D Hönemann et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Sequence analysis identifies TTRAP, a protein that associates with CD40 and TNF receptor-associated factors, as a member of a superfamily of divalent cation-dependent phosphodiesterases
F Rodrigues-Lima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes
KS Boles et al.
IMMUNOLOGICAL REVIEWS (2001)
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
DNA double-strand breaks: signaling, repair and the cancer connection
KK Khanna et al.
NATURE GENETICS (2001)
Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies
G Rozenfeld-Granot et al.
EXPERIMENTAL HEMATOLOGY (2001)
Human CD38: a (r)evolutionary story of enzymes and receptors
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1
M Jourdan et al.
CELL DEATH AND DIFFERENTIATION (2000)
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
P Moreau et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development
YJ Gao et al.
NATURE (2000)
The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells
SG Tangye et al.
SEMINARS IN IMMUNOLOGY (2000)
Activin A is an essential cofactor for osteoclast induction
K Fuller et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
MJ Difilippantonio et al.
NATURE (2000)
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors
ZJ Gu et al.
LEUKEMIA (2000)
Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone
P Tassone et al.
CELL DEATH AND DIFFERENTIATION (2000)
分享论文
